This is a working overview of shelf life, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-30 and is reviewed periodically as new material appears.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
=== Structural domains === Structural domains mediate attachment of other proteins to membranes. Their binding to membranes can be mediated by calcium ions (Ca2+) that form bridges between the acidic protein residues and phosphate groups of lipids, as in annexins or GLA domains.
The volatilities for niobium and tantalum were similar within error limits, but dubnium appeared to be significantly less volatile. It was postulated that traces of oxygen in the system might have led to formation of DbOBr3, which was predicted to be less volatile than DbBr5. Later experiments in 1996 showed that group 5 chlorides were more volatile than the corresponding bromides, with the exception of tantalum, presumably due to formation of TaOCl3. Later volatility studies of chlorides of dubnium and niobium as a function of controlled partial pressures of oxygen showed that formation of oxychlorides and general volatility are dependent on concentrations of oxygen. The oxychlorides were shown to be less volatile than the chlorides. In 2004–05, researchers from Dubna and Livermore identified a new dubnium isotope, 268Db, as a fivefold alpha decay product of the newly created element 115. This new isotope proved to be long-lived enough to allow further chemical experimentation, with a half-life of over a day. In the 2004 experiment, a thin layer with dubnium was removed from the surface of the target and dissolved in aqua regia with tracers and a lanthanum carrier, from which various +3, +4, and +5 species were precipitated on adding ammonium hydroxide. The precipitate was washed and dissolved in hydrochloric acid, where it converted to nitrate form and was then dried on a film and counted.
== External links == Laws, ordinances, guidelines, expert opinions and publications on radiation protection Archived 2018-03-18 at the Wayback Machine, timeline since 2002 of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection. Retrieved on November 28, 2017. Guidelines for quality assurance in radiology Archived 2013-07-15 at the Wayback Machine (PDF) German Medical Association, November 23, 2007. Retrieved December 4, 2017. DIN Radiology Standards Archived 2013-07-15 at the Wayback Machine (PDF) DIN Radiology Standards Committee NAR in cooperation with the German Radiological Society, June 2015, accessed December 4, 2017. Radiation protection in veterinary medicine - Guideline to the Radiation Protection Ordinance (StrlSchV) and the X-ray Ordinance (RöV) (PDF) September 25, 2014, Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Division Medical-Biological Affairs of Radiation Protection Ref. RS II 4 - 11432/7. Retrieved November 28, 2017. Radioactivity and radiation protection (PDF; 6.6 MB) Federal Office of Public Health (Switzerland), July 2007, accessed November 25, 2017. Overview of international radiation protection associations and organizations, Austrian Association for Radiation Protection. Retrieved December 3, 2017. Human Radiation Experiments DOE Openness. Retrieved January 10, 2018. Department of Energy OpenNet Resources. Retrieved January 10, 2018. Igor Gusev, Angelina Guskova, Fred A. Mettler: Medical Management of Radiation Accidents, Second Edition.
CH2=CH(NH2)CO2H + H2O → CH3−C(O)CO2H + NH3 N-Acylated derivatives of dehydroalanine, such as are found peptides and related compounds, are stable. One such example is methyl 2-acetamidoacrylate. As a residue in a peptide, dehydroalanine is generated by a post translational modification. The required precursors are serine or cysteine residues, which undergo enzyme-mediated loss of water and hydrogen sulfide, respectively. Most amino acid residues are unreactive toward nucleophiles, but those containing dehydroalanine or some other dehydroamino acids are exceptions. These residues are electrophilic due to the α,β-unsaturated carbonyl, and can, for example, alkylate other amino acids. This activity has made DHA useful synthetically to prepare lanthionine.
=== Neonatal abstinence === Buprenorphine has been used in the treatment of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application. Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.
Sources: en.wikipedia.org
When SCLC is found with one or more differentiated forms of lung cancer, such as squamous cell carcinoma or adenocarcinoma, the malignant tumor is then diagnosed and classified as a combined small cell lung carcinoma (c-SCLC). Small-cell lung carcinoma can occur in combination with a wide variety of other histological variants of lung cancer, including extremely complex malignant tissue admixtures.
Hegseth's former sister-in-law, Danielle, sent an affidavit to senators alleging that he was abusive to his second wife, Samantha, and that he had issues with over-consumption of alcohol. Hegseth denied having a drinking problem and pledged not to drink if confirmed. On January 24, Hegseth was confirmed by the Senate in a 51–50 vote. Every Republican senator, with the exception of Susan Collins, Lisa Murkowski, and Mitch McConnell, voted to confirm him, while every Democratic senator opposed his nomination, leading to a 50–50 vote. Vance cast a tie-breaking vote to confirm Hegseth. His confirmation was threatened by Senator Thom Tillis, who told Senate majority leader John Thune the day before that he would not vote for Hegseth on the basis of his sexual assault allegations. Persuaded by Vance, Tillis expressed support for Hegseth on X minutes before the vote. His confirmation was the second in US history to be decided by a vice president, after Betsy DeVos's confirmation for secretary of education in 2017.
=== Greek life, social clubs, and organizations === Morgan State University has over 20+ fraternity and sorority chapters including the nine National Pan-Hellenic Council (NPHC) organizations, social fellowships, clubs, student government association (SGA), and free purpose recreation spaces.
This layer acts as a nucleation site during the next step, where a process of electroless deposition layers a coating of gold on the nanotubes to form metal-insulator-metal trilayer coaxial nanocables. Peptide nanotubes are able to produce nanowires of uniform size, and this is particularly useful in the nano-electric applications as electrical and magnetic properties are sensitive to size. Nanotubes' exceptional mechanical strength and stability makes them excellent materials for application in this area. Nanotubes have also been used in developing electrochemical biosensing platforms and have proved to have great potential. Dipeptide nanotubes deposited on graphite electrodes improved electrode sensitivity; thiol-modified nanotubes deposited on gold with a coating of enzymes improved sensitivity and reproducibility for the detection of glucose and ethanol, as well as a shortened detection time, large current density, and improved stability. Nanotubes have also been successfully coated with proteins, nanocrystals, and metalloporphyrin through hydrogen bonding, and these coated tubes have great potential as chemical sensors. Designed peptides with a known structure that would self-assemble into a regular growth template would enable the self-assembly of nanoscale electronic circuits and devices. However, one issue that has yet to be resolved is the ability to control the positioning of the nanostructures. This positioning relative to substrates, to each other, and to other functional components is crucial.
== History == Phenibut was synthesized at the A. I. Herzen Leningrad Pedagogical Institute (USSR) by Professor Vsevolod Perekalin's team and tested at the Institute of Experimental Medicine, USSR Academy of Medical Sciences. It was introduced into clinical use in Russia in the 1960s.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.